InfuSystem Holdings president and COO Carrie Lachance buys $18,986 in stock

Published 19/05/2025, 13:04
InfuSystem Holdings president and COO Carrie Lachance buys $18,986 in stock

In a recent move, Carrie Lachance, President and Chief Operating Officer of InfuSystem Holdings, Inc. (NYSE:INFU), acquired additional shares in the company. According to a filing submitted to the Securities and Exchange Commission, Lachance purchased a total of 3,132 shares over two days, with transactions occurring on May 15 and May 16, 2025. The shares were bought at a weighted average price ranging between $6.005 and $6.096 per share, amounting to a total purchase value of $18,986. This insider purchase comes as the stock has shown strong momentum, with a 12% return over the past week. According to InvestingPro data, management has been actively buying back shares, demonstrating confidence in the company’s prospects.

Following these transactions, Lachance now directly owns 190,212 shares of InfuSystem Holdings. This increase in her holdings reflects her continued confidence in the company’s prospects. The company appears undervalued according to InvestingPro Fair Value analysis, with strong fundamentals including a perfect Piotroski Score of 9 and a healthy current ratio of 2.21. The purchases were made in multiple transactions, and the weighted average prices were reported in the filing, with the possibility of further detailed information available upon request. For deeper insights and access to 10+ additional ProTips about INFU, visit InvestingPro.

In other recent news, InfuSystem Holdings Inc . released its Q1 2025 financial results, revealing a mix of outcomes. The company reported an earnings per share (EPS) of -$0.01, missing the forecast of $0.02. Despite this, revenue exceeded expectations, reaching $34.7 million compared to the anticipated $34.07 million. InfuSystem’s revenue saw an 8.5% increase year-over-year, with adjusted EBITDA rising by 64% from the previous year to $6.3 million. The company is projecting full-year revenue growth between 8% and 10%. InfuSystem’s strategic focus remains on advanced wound care and chemo mouthpiece products, aiming for capital-efficient growth and improved profitability. Additionally, the company is undergoing a leadership transition, with Carrie LeChance stepping in as the new CEO. Investors showed optimism about these developments, as reflected in the stock’s performance following the earnings announcement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.